In this way (Table 3), an increased risk for RCC among alpha-1 blocker users was observed in the subgroup of patients without BPH (adjusted HR, 1.64; 95% CI, 1.33−2.22; P < .001) but not in those with BPH (adjusted HR, 0.95; 95% CI, 0.51−1.17; P < .001). Here, PSMA6 is linked to renal cell carcinoma.